Fragile X Syndrome

🔗

Mappings

MONDO

MONDO:0010383 fragile X syndrome

Orphanet lists MONDO:0010383 as an exact cross-reference for fragile X syndrome.

ICD-10-CM

ICD10CM:Q99.2 Fragile X chromosome

Orphanet lists ICD-10 Q99.2 as an exact cross-reference for fragile X syndrome.

ICD-11 Foundation

icd11f:1524287677 Fragile X chromosome

Orphanet lists ICD-11 LD55 as an exact cross-reference; the local ICD-11 Foundation ontology represents this as icd11f:1524287677.

👪

Inheritance

1

X-linked dominant inheritance HP:0001423

Orphanet classifies fragile X syndrome as X-linked dominant; clinical expression is typically more severe in affected males and variable in heterozygous females.

X-linked dominant inheritance

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"X-linked dominant"

Orphanet directly lists X-linked dominant inheritance for Fragile X syndrome.

◆

Subtypes

2

Full Mutation

More than 200 CGG repeats with methylation, full syndrome expression in males.

FMR1 Carrier

55-200 CGG repeats, risk for FXTAS (tremor-ataxia) and FXPOI in carriers.

◈

Mechanistic Hypotheses

1

Canonical FMR1 Silencing / FMRP Loss / Synaptic Translation Dysregulation Model

canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model CANONICAL

Fragile X syndrome (FXS) is caused by CGG-trinucleotide repeat expansion (>200 repeats) in the 5' UTR of FMR1 on Xq27.3, leading to hypermethylation and transcriptional silencing of FMR1 and loss of its protein product FMRP. FMRP is an RNA-binding protein that represses translation of hundreds of synaptic mRNAs at dendrites and is required for the metabotropic glutamate receptor (mGluR)-dependent regulation of synaptic protein synthesis. Loss of FMRP produces excessive and de- coupled local protein synthesis, leading to exaggerated mGluR-LTD, abnormal dendritic spine morphology, altered excitatory/inhibitory balance, and the cognitive, behavioral, and somatic phenotypes of FXS. mGluR5 antagonists, GABAergic modulators, and IGF-1 / BDNF / MAPK-pathway perturbation studies in Fmr1-knockout mice and human iPSC-derived neurons all corroborate the canonical FMRP-loss / dysregulated synaptic-translation model.

Retained as CANONICAL with hub-and-spoke annotation. The 2026 openscientist hypothesis-search report (kb/hypotheses/Fragile_X_Syndrome/canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model) confirms CGG-expansion → FMR1 silencing → FMRP loss as the central lesion, with dCas9-Tet1 demethylation rescuing FMR1 expression and neuronal phenotypes (>5% FMRP restoration sufficient) providing the strongest causal proof. FMRP target mRNAs are enriched among de novo mutations in schizophrenia, autism, and intellectual disability, validating FMRP as a central translational regulator. Three critical refinements: (1) clinical translation failure — multiple Phase 2b mGluR5- antagonist trials failed in FXS patients, attributed by expert consensus to trial design but the question remains open; (2) mechanistic scope must expand beyond synaptic translation — FMRP has critical non-synaptic functions in genome stability (R-loop prevention), chromatin regulation (BRD4), astrocyte- autonomous GABA transport, and metabolic programming; (3) phenotypes are age- and condition-dependent — enhanced mGluR-LTD is restricted to the P30–60 age window in mice; spine density normalizes by adulthood while dendritic complexity progressively worsens. The report recommends annotating the model as a hub-and-spoke architecture in which FMRP loss disrupts multiple parallel effector arms, with synaptic translation being the best-studied but not the sole driver of clinical phenotypes.

Deep research

OpenScientist citations 55 citations 2026-05-23T23:04:42.114391

Show evidence (1 reference)

PMID:24346713 SUPPORT Other

"Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."

Canonical mechanism reference used as the seed for the hypothesis-search deep-research run.

⚙

Pathophysiology

7

FMR1 full-mutation transcriptional silencing

The canonical initiating event is expansion of the FMR1 5' UTR CGG repeat above 200 repeats. Full-mutation alleles become epigenetically silenced in differentiated cells, which reduces or abolishes fragile X messenger ribonucleoprotein (FMRP).

Downstream

FMRP loss of translational repression Epigenetic silencing of the full-mutation FMR1 allele decreases FMRP, removing a key RNA-binding translational repressor.

Show evidence (2 references)

PMID:28420439 SUPPORT Human Clinical

"more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS."

This review establishes the full-mutation CGG expansion as the dominant molecular diagnosis for fragile X syndrome.

PMID:27713816 SUPPORT In Vitro

"Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory."

Patient-derived stem-cell and neuronal differentiation work supports epigenetic silencing of full-mutation alleles and consequent FMRP loss.

FMRP loss of translational repression

FMRP normally binds coding and non-coding RNAs and restrains translation at dendritic and synaptic locations. Loss of FMRP removes this brake, increasing basal protein translation and uncoupling translation from neuronal activity.

neuron link

negative regulation of translation link ↓ DECREASED

Downstream

Synaptic protein synthesis and mGluR signaling dysregulation Loss of FMRP increases basal translation and disrupts mGluR-triggered translational control at synapses.

Connective tissue and testicular phenotype expression FMRP deficiency is upstream of the multisystem physical phenotype, though the intermediate tissue mechanisms are less resolved than the synaptic neurodevelopmental branch.

Show evidence (2 references)

PMID:24346713 SUPPORT Other

"Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."

This directly supports FMRP as a translational repressor at neuronal dendritic and synaptic sites.

PMID:22483044 SUPPORT Other

"FMRP is an mRNA-binding protein that functions at many synapses to inhibit local translation stimulated by metabotropic glutamate receptors (mGluRs) 1 and 5."

This supports the mechanism linking FMRP loss to dysregulated local synaptic translation.

Synaptic protein synthesis and mGluR signaling dysregulation

With FMRP absent, basal translation is enhanced and mGluR1/5-linked local translation is no longer appropriately regulated. This distorts the experience-dependent protein synthesis needed for synaptic plasticity.

neuron link

regulation of synaptic plasticity link

Downstream

Dendritic spine and synapse maturation abnormality Dysregulated local translation alters synaptic plasticity programs that shape dendritic spine and synapse maturation.

Neurodevelopmental circuit dysfunction Abnormal synaptic protein synthesis and plasticity impair the neural circuit functions required for cognition, social behavior, and attention.

Show evidence (2 references)

PMID:24346713 SUPPORT Other

"In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation."

This supports enhanced basal protein translation after FMRP loss.

PMID:22483044 SUPPORT Other

"Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience."

This places mGluR1/5-linked signaling and synaptic protein synthesis within the fragile X pathophysiology framework.

Dendritic spine and synapse maturation abnormality

FMRP loss disrupts synapse structure and dendritic spine maturation. Patient and model-system literature consistently links fragile X syndrome to altered structural and functional synaptic plasticity, with cell-type and brain-region-specific changes in synapse density and spine morphology.

neuron link

synapse organization link protein localization to synapse link

Downstream

Neurodevelopmental circuit dysfunction Altered synapse and spine maturation disrupts network-level signaling needed for cognition and behavior.

Neuronal hyperexcitability Synaptic dysregulation contributes to increased neuronal excitability and seizure susceptibility in a subset of affected individuals.

Show evidence (2 references)

PMID:33013316 SUPPORT In Vitro

"Loss of FMRP, as in fragile X syndrome (FXS), is a leading monogenic cause of autism and results in altered structural and functional synaptic plasticity, widely described in the hippocampus and cortex."

This supports altered structural and functional synaptic plasticity as a downstream effect of FMRP loss.

PMID:33013316 SUPPORT In Vitro

"Utilizing a cortical-striatal co-culture model, we find that striatal medium spiny neurons (MSNs) lacking FMRP fail to make normal increases in PSD95 expression over a short time period and have significant deficits in dendritic spine density and colocalized synaptic puncta at the later measured..."

This in vitro model links FMRP loss to abnormal postsynaptic marker expression, dendritic spine density, and synaptic puncta.

Neurodevelopmental circuit dysfunction

Synaptic translation and spine abnormalities converge on disrupted neural circuit development and function. This branch accounts for the core cognitive and behavioral manifestations of fragile X syndrome, including intellectual disability, autistic behavior, and hyperactivity.

neuron link

central nervous system development link regulation of synaptic plasticity link

Downstream

Intellectual Disability Neurodevelopmental circuit dysfunction impairs intellectual and adaptive functioning.

Autism Spectrum Features Altered circuit development contributes to autistic behavior and social communication deficits.

Hyperactivity Circuit-level dysfunction contributes to attention problems and hyperactive behavior.

Anxiety Circuit-level dysfunction contributes to anxiety, shyness, and related social-avoidance behavior in fragile X syndrome.

Show evidence (1 reference)

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This ties the neurodevelopmental phenotypes to FMR1 silencing and FMRP loss.

Neuronal hyperexcitability

A subset of individuals with fragile X syndrome develop seizures. FMRP deficiency is proposed to increase neuronal excitability and susceptibility to epilepsy, often with childhood-onset focal seizure patterns.

neuron link

Downstream

Seizures Increased neuronal excitability increases susceptibility to epilepsy and seizure manifestations.

Show evidence (1 reference)

PMID:12418611 SUPPORT Human Clinical

"Deficiency of FMRP (fragile X mental retardation protein) appears to lead to increased neuronal excitability and susceptibility to epilepsy, but particularly seems to facilitate mechanisms leading to the BFEC pattern."

This clinical review explicitly connects FMRP deficiency to neuronal excitability and epilepsy susceptibility in fragile X syndrome.

Connective tissue and testicular phenotype expression

Fragile X syndrome has a multisystem physical branch characterized by long face, prominent or large ears, hyperextensible joints, and macroorchidism in males. The precise tissue intermediates downstream of FMRP deficiency are less complete than the neuronal mechanism, so this node represents the clinically observed physical phenotype branch.

fibroblast link Sertoli cell link

connective tissue development link germ cell development link

Downstream

Elongated Face The physical phenotype branch produces the long facial gestalt of fragile X syndrome.

Large Ears The physical phenotype branch includes large or prominent ears.

Joint Hypermobility Connective-tissue involvement contributes to hyperextensible joints.

Macroorchidism Testicular phenotype expression contributes to macroorchidism in males, especially after later childhood and puberty.

Show evidence (3 references)

PMID:28420439 SUPPORT Human Clinical

"The clinical spectrum of FXS is wide, presenting not only as an isolated intellectual disability but as a multi-systemic condition, involving predominantly the central nervous system but potentially affecting any apparatus."

This supports representing fragile X syndrome as a multisystem condition rather than a solely neuronal disorder.

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This directly supports the craniofacial and connective-tissue branch of the physical phenotype.

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This supports the combined cognitive, behavioral, craniofacial, and macroorchidism phenotype profile.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

18

Digestive 1

Gastroesophageal Reflux Gastroesophageal reflux (HP:0002020)

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media"

GeneReviews lists gastroesophageal reflux as a recognized medical problem in FXS.

Ear 2

Large Ears FREQUENT Macrotia (HP:0000400)

Show evidence (3 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This directly supports large/protruding ears as part of the fragile X physical phenotype.

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This supports prominent ears across affected males and females.

ORPHA:908 SUPPORT Other

"HP:0000400 | Macrotia | Frequent (79-30%)"

Orphanet's curated HPO table classifies macrotia, the HPO term used here, as frequent in Fragile X syndrome.

Chronic Otitis Media VERY_FREQUENT Chronic otitis media (HP:0000389)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0000389 | Chronic otitis media | Very frequent (99-80%)"

Orphanet's curated HPO table classifies chronic otitis media as very frequent in Fragile X syndrome.

Genitourinary 1

Macroorchidism VERY_FREQUENT Macroorchidism (HP:0000053)

Show evidence (3 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This clinical review identifies macroorchidism as part of the fragile X physical phenotype.

PMID:8190590 SUPPORT Human Clinical

"Macroorchidism is one of the most well-described clinical characteristics of men with fragile X syndrome, but little information has been available regarding macroorchidism in prepubertal boys with fragile X."

This study supports macroorchidism as a well-described male clinical characteristic and clarifies age-related expression.

ORPHA:908 SUPPORT Other

"HP:0000053 | Macroorchidism | Very frequent (99-80%)"

Orphanet's curated HPO table classifies macroorchidism as very frequent in Fragile X syndrome.

Head and Neck 1

Elongated Face FREQUENT Long face (HP:0000276)

Show evidence (3 references)

PMID:9678703 SUPPORT Human Clinical

"The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism."

This directly supports long face as part of the fragile X physical phenotype.

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This supports long face across affected males and females.

ORPHA:908 SUPPORT Other

"HP:0000276 | Long face | Frequent (79-30%)"

Orphanet's curated HPO table classifies long face as frequent in Fragile X syndrome.

Limbs 1

Pes Planus VERY_FREQUENT Pes planus (HP:0001763)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0001763 | Pes planus | Very frequent (99-80%)"

Orphanet's curated HPO table classifies pes planus as very frequent in Fragile X syndrome.

Musculoskeletal 2

Hypotonia FREQUENT Hypotonia (HP:0001252)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0001252 | Hypotonia | Frequent (79-30%)"

Orphanet's curated HPO table classifies hypotonia as frequent in Fragile X syndrome.

Joint Hypermobility VERY_FREQUENT Joint hypermobility (HP:0001382)

Show evidence (2 references)

PMID:8237919 SUPPORT Human Clinical

"The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females."

This directly supports hyperextensible joints as part of the fragile X physical phenotype.

ORPHA:908 SUPPORT Other

"HP:0001382 | Joint hypermobility | Very frequent (99-80%)"

Orphanet's curated HPO table classifies joint hypermobility as very frequent in Fragile X syndrome.

Nervous System 9

Sleep Disturbance Sleep disturbance (HP:0002360)

Show evidence (1 reference)

PMID:20301558 SUPPORT Other

"medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media"

GeneReviews lists sleep disorders as a recognized medical problem in FXS.

Intellectual Disability Intellectual disability (HP:0001249)

Show evidence (1 reference)

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This supports intellectual disability as a core fragile X manifestation linked to FMR1 silencing and FMRP loss.

Autism Spectrum Features Autistic behavior (HP:0000729)

Show evidence (2 references)

PMID:22974167 SUPPORT Human Clinical

"Fragile X syndrome (FXS) is the leading genetic cause of autism, accounting for approximately 5% of autism cases with as many as 50% of individuals with FXS meeting DSM-IV-TR criteria for autistic disorder."

This review supports autism as a frequent comorbid neurodevelopmental phenotype in fragile X syndrome.

PMID:22483044 SUPPORT Human Clinical

"Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein)."

This supports the FMR1/FMRP mechanistic link to autism-related features.

Hyperactivity Hyperactivity (HP:0000752)

Show evidence (2 references)

PMID:14730483 SUPPORT Human Clinical

"The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness."

This clinical comparison identifies hyperactivity among characteristic fragile X behavioral features.

PMID:24352914 SUPPORT Human Clinical

"Measures of anxiety, attention, and hyperactivity were highly associated with behavior problems, suggesting that these factors at least coincide with problem behavior."

This full-mutation fragile X caregiver study supports hyperactivity as a clinically measured behavioral dimension in fragile X syndrome.

Attention Deficit Hyperactivity Disorder FREQUENT Attention deficit hyperactivity disorder (HP:0007018)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"

Orphanet's curated HPO table classifies attention deficit hyperactivity disorder as frequent in Fragile X syndrome.

Anxiety OCCASIONAL Anxiety (HP:0000739)

Show evidence (2 references)

PMID:14730483 SUPPORT Human Clinical

"The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness."

This clinical comparison identifies anxiety as a characteristic fragile X behavioral feature linked to the genetic disorder.

ORPHA:908 SUPPORT Other

"HP:0000739 | Anxiety | Occasional (29-5%)"

Orphanet's curated HPO table classifies anxiety as occasional in Fragile X syndrome.

Seizures OCCASIONAL Seizure (HP:0001250)

Show evidence (2 references)

PMID:12418611 SUPPORT Human Clinical

"Seizures occurred in 15 males (13.3%) and one female (4.8%): of these, 12 had partial seizures."

This cohort supports seizures as a recurrent neurological manifestation of fragile X syndrome.

ORPHA:908 SUPPORT Other

"HP:0001250 | Seizure | Occasional (29-5%)"

Orphanet's curated HPO table classifies seizures as occasional in Fragile X syndrome.

Delayed Speech and Language Development FREQUENT Delayed speech and language development (HP:0000750)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0000750 | Delayed speech and language development | Frequent (79-30%)"

Orphanet's curated HPO table classifies delayed speech and language development as frequent in Fragile X syndrome.

Abnormality of Speech or Vocalization VERY_FREQUENT Abnormal speech pattern (HP:0002167)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"

Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Fragile X syndrome.

Other 1

Moderate Intellectual Disability VERY_FREQUENT Moderate intellectual disability (HP:0002342)

Show evidence (1 reference)

ORPHA:908 SUPPORT Other

"HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"

Orphanet's curated HPO table classifies moderate intellectual disability as very frequent in Fragile X syndrome.

🧬

Genetic Associations

1

FMR1 (Causative full-mutation CGG repeat expansion)

Show evidence (3 references)

PMID:28420439 SUPPORT Human Clinical

"It is caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS."

This review supports FMR1 as the causal gene and identifies full-mutation CGG repeat expansion as the dominant pathogenic variant class.

PMID:24346713 SUPPORT Other

"Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene."

This supports the causal FMR1 gene-disease relationship.

CGGV:assertion_e491d278-7123-434c-8de3-46e16afb4037-2019-06-03T160000.000Z SUPPORT Other

ClinGen classifies the FMR1-fragile X syndrome gene-disease relationship as definitive with X-linked inheritance.

💊

Treatments

5

Behavioral Therapy

Action: applied behavior analysis therapy MAXO:0001359

Applied behavior analysis and educational interventions for cognitive and behavioral symptoms.

Speech Therapy

Action: speech therapy MAXO:0000930

Language and communication support.

Stimulant Medications

Action: Pharmacotherapy NCIT:C15986

Agent: CNS Stimulant ↗

For attention deficit and hyperactivity symptoms.

SSRIs

Action: Pharmacotherapy NCIT:C15986

Agent: Selective Serotonin Reuptake Inhibitor ↗

For anxiety and mood symptoms.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Family screening for FMR1 expansion carriers, prenatal testing options.

🔬

Biochemical Markers

1

FMRP (Absent or reduced)

Context: Absent in full-mutation males; variably reduced in females and mosaic individuals.

Show evidence (1 reference)

PMID:27713816 SUPPORT In Vitro

"Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory."

This supports FMRP loss as the biochemical consequence of full-mutation FMR1 silencing.

🔬

Clinical Trials

2

NCT02920892 PHASE_III COMPLETED

FXLEARN phase 3 randomized trial of AFQ056/mavoglurant for language learning in young children with fragile X syndrome; the published trial did not show significant benefit over placebo on the primary WCS language outcome.

Target Phenotypes: Delayed speech and language development ↗

Show evidence (2 references)

clinicaltrials:NCT02920892 SUPPORT Human Clinical

"The purpose of this clinical trial is to investigate the impact of AFQ056 on language learning in 3-6 year old children with Fragile X Syndrome (FXS)."

ClinicalTrials.gov documents the AFQ056 language-learning trial in young children with fragile X syndrome.

PMID:37651202 SUPPORT Human Clinical

"Although both groups made language progress and there were no safety issues, the change in WCS score during the placebo-controlled period was not significantly different between the AFQ056 and placebo-treated groups, nor were there any significant between-group differences in change in any..."

The published FXLEARN report supports the completed phase 3 trial and its negative primary and secondary efficacy results.

NCT03569631 PHASE_II COMPLETED

Phase 2a randomized double-blind crossover trial of BPN14770/zatolmilast in adult males with fragile X syndrome, with published cognition, language, daily-functioning, and EEG biomarker analyses.

Target Phenotypes: Intellectual disability ↗

Show evidence (2 references)

clinicaltrials:NCT03569631 SUPPORT Human Clinical

"This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome."

ClinicalTrials.gov documents the BPN14770 crossover trial in adult males with fragile X syndrome.

DOI:10.1186/s13229-024-00626-0 SUPPORT Human Clinical

"A recent phase 2a clinical trial testing BPN14770, a phosphodiesterase 4D inhibitor, showed improved cognition in 30 adult males with FXS on drug relative to placebo."

The Molecular Autism biomarker analysis supports the phase 2a BPN14770 trial and its reported cognition signal.

{ }

Source YAML

click to show

name: Fragile X Syndrome
creation_date: '2026-01-07T17:31:51Z'
updated_date: '2026-04-28T06:33:33Z'
category: Genetic
parents:
- Intellectual Disability Syndrome
- Trinucleotide Repeat Disorder
disease_term:
  preferred_term: fragile X syndrome
  term:
    id: MONDO:0010383
    label: fragile X syndrome
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:Q99.2
      label: Fragile X chromosome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: Orphanet lists ICD-10 Q99.2 as an exact cross-reference for fragile X syndrome.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "ICD-10:Q99.2 | Exact"
  icd11f_mappings:
  - term:
      id: icd11f:1524287677
      label: Fragile X chromosome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: >-
      Orphanet lists ICD-11 LD55 as an exact cross-reference; the local
      ICD-11 Foundation ontology represents this as icd11f:1524287677.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "ICD-11:LD55 | Exact"
  mondo_mappings:
  - term:
      id: MONDO:0010383
      label: fragile X syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:908
    mapping_justification: Orphanet lists MONDO:0010383 as an exact cross-reference for fragile X syndrome.
    consistency:
    - reference: ORPHA:908
      consistent: CONSISTENT
      notes: "MONDO:0010383 | Exact"
external_assertions:
- name: Orphanet Fragile X syndrome record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:908
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=908
  description: >-
    Orphanet curates ORPHA:908 as the Fragile X syndrome structured disease
    record and provides exact cross-references to MONDO, ICD-10, ICD-11, MeSH,
    MedDRA, UMLS, and other identifiers.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:908  Fragile X syndrome"
    explanation: The Orphanet structured record heading identifies ORPHA:908 as the Fragile X syndrome disease record.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010383 | Exact"
    explanation: Orphanet maps ORPHA:908 exactly to the same MONDO disease identifier used as this entry's disease term.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:Q99.2 | Exact"
    explanation: Orphanet provides an exact ICD-10 cross-reference for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:LD55 | Exact"
    explanation: Orphanet provides an exact ICD-11 cross-reference for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "UMLS:C0016667 | Exact"
    explanation: Orphanet provides an exact UMLS cross-reference for Fragile X syndrome.
has_subtypes:
- name: Full Mutation
  description: More than 200 CGG repeats with methylation, full syndrome expression in males.
- name: FMR1 Carrier
  description: 55-200 CGG repeats, risk for FXTAS (tremor-ataxia) and FXPOI in carriers.
inheritance:
- name: X-linked dominant inheritance
  inheritance_term:
    preferred_term: X-linked dominant inheritance
    term:
      id: HP:0001423
      label: X-linked dominant inheritance
  description: >-
    Orphanet classifies fragile X syndrome as X-linked dominant; clinical
    expression is typically more severe in affected males and variable in
    heterozygous females.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "X-linked dominant"
    explanation: Orphanet directly lists X-linked dominant inheritance for Fragile X syndrome.
prevalence:
- population: General population
  percentage: 1.4 per 10,000 males; 0.9 per 10,000 females
  notes: >-
    Meta-analysis estimates the full FMR1 mutation frequency at about 1 in
    7,143 males and 1 in 11,111 females in the total population.
  evidence:
  - reference: PMID:24700618
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using the random-effects model, frequency of the full mutation was 1.4 (95% CI: 0.1-3.1) per 10,000 males and 0.9 (95% CI: 0.0-2.9) per 10,000 females (1:7,143 and 1:11,111, respectively) in the total population."
    explanation: This systematic review and meta-analysis provides pooled sex-specific full-mutation frequencies for fragile X syndrome.
  - reference: PMID:9032640
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Revised prevalence figures have been calculated giving rise to an overall prevalence figure of 1/2720 (range 1/2198-1/3089). If the four children lost to follow up are also assumed not to have the fragile X syndrome, the revised prevalence figure was 1/5714 (range 1/4762-1/6349)."
    explanation: This molecular re-evaluation of an older population cohort supports that fragile X syndrome prevalence is lower than earlier historical estimates and within the rare-disease range.
- population: Worldwide (Orphanet point prevalence)
  percentage: "1-5 / 10 000"
  notes: Orphanet reports a worldwide point-prevalence class of 1-5 per 10,000.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Worldwide | Point prevalence | PMID:18413371,EXPERT"
    explanation: The Orphanet epidemiology table provides a worldwide point-prevalence class for Fragile X syndrome.
progression:
- phase: Onset
  age_range: Neonatal to childhood
  notes: Orphanet lists neonatal, infancy, and childhood onset categories for Fragile X syndrome.
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Neonatal"
    explanation: Orphanet records neonatal onset as one natural-history category for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Infancy"
    explanation: Orphanet records infantile onset as one natural-history category for Fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: Orphanet records childhood onset as one natural-history category for Fragile X syndrome.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model
  hypothesis_label: Canonical FMR1 Silencing / FMRP Loss / Synaptic Translation Dysregulation Model
  status: CANONICAL
  description: >-
    Fragile X syndrome (FXS) is caused by CGG-trinucleotide repeat expansion (>200 repeats) in the 5'
    UTR of FMR1 on Xq27.3, leading to hypermethylation and transcriptional silencing of FMR1 and loss of
    its protein product FMRP. FMRP is an RNA-binding protein that represses translation of hundreds of
    synaptic mRNAs at dendrites and is required for the metabotropic glutamate receptor
    (mGluR)-dependent regulation of synaptic protein synthesis. Loss of FMRP produces excessive and de-
    coupled local protein synthesis, leading to exaggerated mGluR-LTD, abnormal dendritic spine
    morphology, altered excitatory/inhibitory balance, and the cognitive, behavioral, and somatic
    phenotypes of FXS. mGluR5 antagonists, GABAergic modulators, and IGF-1 / BDNF / MAPK-pathway
    perturbation studies in Fmr1-knockout mice and human iPSC-derived neurons all corroborate the
    canonical FMRP-loss / dysregulated synaptic-translation model.
  notes: >-
    Retained as CANONICAL with hub-and-spoke
    annotation. The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Fragile_X_Syndrome/canonical_fmr1_silencing_fmrp_loss_synaptic_dysregulation_model)
    confirms CGG-expansion → FMR1 silencing → FMRP loss as the
    central lesion, with dCas9-Tet1 demethylation rescuing FMR1
    expression and neuronal phenotypes (>5% FMRP restoration
    sufficient) providing the strongest causal proof. FMRP target
    mRNAs are enriched among de novo mutations in schizophrenia,
    autism, and intellectual disability, validating FMRP as a
    central translational regulator. Three critical refinements:
    (1) clinical translation failure — multiple Phase 2b mGluR5-
    antagonist trials failed in FXS patients, attributed by expert
    consensus to trial design but the question remains open;
    (2) mechanistic scope must expand beyond synaptic translation —
    FMRP has critical non-synaptic functions in genome stability
    (R-loop prevention), chromatin regulation (BRD4), astrocyte-
    autonomous GABA transport, and metabolic programming;
    (3) phenotypes are age- and condition-dependent — enhanced
    mGluR-LTD is restricted to the P30–60 age window in mice;
    spine density normalizes by adulthood while dendritic
    complexity progressively worsens. The report recommends
    annotating the model as a hub-and-spoke architecture in which
    FMRP loss disrupts multiple parallel effector arms, with
    synaptic translation being the best-studied but not the sole
    driver of clinical phenotypes.
  evidence:
  - reference: PMID:24346713
    reference_title: "From FMRP function to potential therapies for fragile X syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations."
    explanation: >
      Canonical mechanism reference used as the seed for the
      hypothesis-search deep-research run.
pathophysiology:
- name: FMR1 full-mutation transcriptional silencing
  description: >-
    The canonical initiating event is expansion of the FMR1 5' UTR CGG repeat
    above 200 repeats. Full-mutation alleles become epigenetically silenced in
    differentiated cells, which reduces or abolishes fragile X messenger
    ribonucleoprotein (FMRP).
  gene:
    preferred_term: FMR1
    modifier: DECREASED
    term:
      id: hgnc:3775
      label: FMR1
  downstream:
  - target: FMRP loss of translational repression
    causal_link_type: DIRECT
    description: >-
      Epigenetic silencing of the full-mutation FMR1 allele decreases FMRP,
      removing a key RNA-binding translational repressor.
  evidence:
  - reference: PMID:28420439
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS.
    explanation: >-
      This review establishes the full-mutation CGG expansion as the dominant
      molecular diagnosis for fragile X syndrome.
  - reference: PMID:27713816
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory.
    explanation: >-
      Patient-derived stem-cell and neuronal differentiation work supports
      epigenetic silencing of full-mutation alleles and consequent FMRP loss.
- name: FMRP loss of translational repression
  description: >-
    FMRP normally binds coding and non-coding RNAs and restrains translation at
    dendritic and synaptic locations. Loss of FMRP removes this brake, increasing
    basal protein translation and uncoupling translation from neuronal activity.
  gene:
    preferred_term: FMR1
    modifier: DECREASED
    term:
      id: hgnc:3775
      label: FMR1
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: negative regulation of translation
    term:
      id: GO:0017148
      label: negative regulation of translation
    modifier: DECREASED
  downstream:
  - target: Synaptic protein synthesis and mGluR signaling dysregulation
    causal_link_type: DIRECT
    description: >-
      Loss of FMRP increases basal translation and disrupts mGluR-triggered
      translational control at synapses.
  - target: Connective tissue and testicular phenotype expression
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      FMRP deficiency is upstream of the multisystem physical phenotype, though
      the intermediate tissue mechanisms are less resolved than the synaptic
      neurodevelopmental branch.
  evidence:
  - reference: PMID:24346713
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Numerous studies have demonstrated that FMRP interacts with both coding and non-coding RNAs and represses protein synthesis at dendritic and synaptic locations.
    explanation: >-
      This directly supports FMRP as a translational repressor at neuronal
      dendritic and synaptic sites.
  - reference: PMID:22483044
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      FMRP is an mRNA-binding protein that functions at many synapses to inhibit local translation stimulated by metabotropic glutamate receptors (mGluRs) 1 and 5.
    explanation: >-
      This supports the mechanism linking FMRP loss to dysregulated local
      synaptic translation.
- name: Synaptic protein synthesis and mGluR signaling dysregulation
  description: >-
    With FMRP absent, basal translation is enhanced and mGluR1/5-linked local
    translation is no longer appropriately regulated. This distorts the
    experience-dependent protein synthesis needed for synaptic plasticity.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  downstream:
  - target: Dendritic spine and synapse maturation abnormality
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Activity-dependent translation of FMRP target RNAs
    - mGluR1/5-linked local protein synthesis
    description: >-
      Dysregulated local translation alters synaptic plasticity programs that
      shape dendritic spine and synapse maturation.
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synaptic protein synthesis
    - Altered synaptic plasticity
    description: >-
      Abnormal synaptic protein synthesis and plasticity impair the neural
      circuit functions required for cognition, social behavior, and attention.
  evidence:
  - reference: PMID:24346713
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In the absence of FMRP, the basal protein translation is enhanced and not responsive to neuronal stimulation.
    explanation: >-
      This supports enhanced basal protein translation after FMRP loss.
  - reference: PMID:22483044
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Recent studies on the biology of FMRP and the signaling pathways downstream of mGluR1/5 have yielded deeper insight into how synaptic protein synthesis and plasticity are regulated by experience.
    explanation: >-
      This places mGluR1/5-linked signaling and synaptic protein synthesis
      within the fragile X pathophysiology framework.
- name: Dendritic spine and synapse maturation abnormality
  description: >-
    FMRP loss disrupts synapse structure and dendritic spine maturation.
    Patient and model-system literature consistently links fragile X syndrome
    to altered structural and functional synaptic plasticity, with cell-type and
    brain-region-specific changes in synapse density and spine morphology.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: synapse organization
    term:
      id: GO:0050808
      label: synapse organization
  - preferred_term: protein localization to synapse
    term:
      id: GO:0035418
      label: protein localization to synapse
  downstream:
  - target: Neurodevelopmental circuit dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synapse density
    - Altered dendritic spine morphology
    description: >-
      Altered synapse and spine maturation disrupts network-level signaling
      needed for cognition and behavior.
  - target: Neuronal hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered synaptic plasticity
    - Altered excitatory and inhibitory balance
    description: >-
      Synaptic dysregulation contributes to increased neuronal excitability and
      seizure susceptibility in a subset of affected individuals.
  evidence:
  - reference: PMID:33013316
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Loss of FMRP, as in fragile X syndrome (FXS), is a leading monogenic cause of autism and results in altered structural and functional synaptic plasticity, widely described in the hippocampus and cortex.
    explanation: >-
      This supports altered structural and functional synaptic plasticity as a
      downstream effect of FMRP loss.
  - reference: PMID:33013316
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Utilizing a cortical-striatal co-culture model, we find that striatal medium spiny neurons (MSNs) lacking FMRP fail to make normal increases in PSD95 expression over a short time period and have significant deficits in dendritic spine density and colocalized synaptic puncta at the later measured time point compared to wildtype (WT) MSNs.
    explanation: >-
      This in vitro model links FMRP loss to abnormal postsynaptic marker
      expression, dendritic spine density, and synaptic puncta.
- name: Neurodevelopmental circuit dysfunction
  description: >-
    Synaptic translation and spine abnormalities converge on disrupted neural
    circuit development and function. This branch accounts for the core
    cognitive and behavioral manifestations of fragile X syndrome, including
    intellectual disability, autistic behavior, and hyperactivity.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: central nervous system development
    term:
      id: GO:0007417
      label: central nervous system development
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  downstream:
  - target: Intellectual Disability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - FMRP loss
    - Dysregulated synaptic translation
    - Altered synaptic plasticity
    description: >-
      Neurodevelopmental circuit dysfunction impairs intellectual and adaptive
      functioning.
  - target: Autism Spectrum Features
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - FMRP loss
    - Altered synaptic plasticity
    - Altered social-behavioral circuits
    description: >-
      Altered circuit development contributes to autistic behavior and social
      communication deficits.
  - target: Hyperactivity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - FMRP loss
    - Altered striatal and cortical circuit function
    description: >-
      Circuit-level dysfunction contributes to attention problems and
      hyperactive behavior.
  - target: Anxiety
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - FMRP loss
    - Altered social-behavioral circuits
    description: >-
      Circuit-level dysfunction contributes to anxiety, shyness, and related
      social-avoidance behavior in fragile X syndrome.
  evidence:
  - reference: PMID:22483044
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This ties the neurodevelopmental phenotypes to FMR1 silencing and FMRP
      loss.
- name: Neuronal hyperexcitability
  description: >-
    A subset of individuals with fragile X syndrome develop seizures. FMRP
    deficiency is proposed to increase neuronal excitability and susceptibility
    to epilepsy, often with childhood-onset focal seizure patterns.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Seizures
    causal_link_type: DIRECT
    description: >-
      Increased neuronal excitability increases susceptibility to epilepsy and
      seizure manifestations.
  evidence:
  - reference: PMID:12418611
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Deficiency of FMRP (fragile X mental retardation protein) appears to lead to increased neuronal excitability and susceptibility to epilepsy, but particularly seems to facilitate mechanisms leading to the BFEC pattern.
    explanation: >-
      This clinical review explicitly connects FMRP deficiency to neuronal
      excitability and epilepsy susceptibility in fragile X syndrome.
- name: Connective tissue and testicular phenotype expression
  description: >-
    Fragile X syndrome has a multisystem physical branch characterized by long
    face, prominent or large ears, hyperextensible joints, and macroorchidism in
    males. The precise tissue intermediates downstream of FMRP deficiency are
    less complete than the neuronal mechanism, so this node represents the
    clinically observed physical phenotype branch.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: Sertoli cell
    term:
      id: CL:0000216
      label: Sertoli cell
  biological_processes:
  - preferred_term: connective tissue development
    term:
      id: GO:0061448
      label: connective tissue development
  - preferred_term: germ cell development
    term:
      id: GO:0007281
      label: germ cell development
  downstream:
  - target: Elongated Face
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The physical phenotype branch produces the long facial gestalt of fragile
      X syndrome.
  - target: Large Ears
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The physical phenotype branch includes large or prominent ears.
  - target: Joint Hypermobility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Connective-tissue involvement contributes to hyperextensible joints.
  - target: Macroorchidism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Testicular phenotype expression contributes to macroorchidism in males,
      especially after later childhood and puberty.
  evidence:
  - reference: PMID:28420439
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The clinical spectrum of FXS is wide, presenting not only as an isolated intellectual disability but as a multi-systemic condition, involving predominantly the central nervous system but potentially affecting any apparatus.
    explanation: >-
      This supports representing fragile X syndrome as a multisystem condition
      rather than a solely neuronal disorder.
  - reference: PMID:8237919
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This directly supports the craniofacial and connective-tissue branch of
      the physical phenotype.
  - reference: PMID:9678703
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This supports the combined cognitive, behavioral, craniofacial, and
      macroorchidism phenotype profile.
phenotypes:
- name: Sleep Disturbance
  category: Neurological
  description: >-
    Sleep problems are common in children with fragile X syndrome and may
    reflect GABAergic and circadian dysregulation.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:20301558
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media"
    explanation: GeneReviews lists sleep disorders as a recognized medical problem in FXS.
- name: Gastroesophageal Reflux
  category: Gastrointestinal
  description: >-
    Gastroesophageal reflux is a recognized medical problem in children with
    fragile X syndrome, often presenting in infancy and early childhood.
  phenotype_term:
    preferred_term: Gastroesophageal reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
  evidence:
  - reference: PMID:20301558
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media"
    explanation: GeneReviews lists gastroesophageal reflux as a recognized medical problem in FXS.
- name: Intellectual Disability
  category: Neurological
  diagnostic: true
  description: >-
    Intellectual disability is a cardinal neurodevelopmental manifestation of
    fragile X syndrome and is generally more severe in males with full-mutation
    FMR1 silencing.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:22483044
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This supports intellectual disability as a core fragile X manifestation
      linked to FMR1 silencing and FMRP loss.
- name: Moderate Intellectual Disability
  category: Neurological
  frequency: VERY_FREQUENT
  description: >-
    Orphanet annotates moderate intellectual disability as a very frequent
    phenotype in Fragile X syndrome.
  phenotype_term:
    preferred_term: Moderate intellectual disability
    term:
      id: HP:0002342
      label: Moderate intellectual disability
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002342 | Intellectual disability, moderate | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies moderate intellectual disability as very frequent in Fragile X syndrome.
- name: Autism Spectrum Features
  category: Behavioral
  description: >-
    Autistic behavior and social communication impairment are common in fragile
    X syndrome; studies vary by ascertainment and diagnostic criteria.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:22974167
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X syndrome (FXS) is the leading genetic cause of autism, accounting for approximately 5% of autism cases with as many as 50% of individuals with FXS meeting DSM-IV-TR criteria for autistic disorder.
    explanation: >-
      This review supports autism as a frequent comorbid neurodevelopmental
      phenotype in fragile X syndrome.
  - reference: PMID:22483044
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Fragile X is the most common known inherited cause of intellectual disability and autism, and it typically results from transcriptional silencing of FMR1 and loss of the encoded protein, FMRP (fragile X mental retardation protein).
    explanation: >-
      This supports the FMR1/FMRP mechanistic link to autism-related features.
- name: Hyperactivity
  category: Behavioral
  description: >-
    Hyperactivity and attention problems are part of the fragile X behavioral
    profile and often co-occur with anxiety and other behavioral challenges.
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  evidence:
  - reference: PMID:14730483
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most characteristic types of conduct seen in FXS include: language problems, lack of attention, hyperactivity, anxiety, shyness, behavioural problems, stereotypical hand flapping, gaze aversion, obstinacy and aggressiveness.
    explanation: >-
      This clinical comparison identifies hyperactivity among characteristic
      fragile X behavioral features.
  - reference: PMID:24352914
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measures of anxiety, attention, and hyperactivity were highly associated with behavior problems, suggesting that these factors at least coincide with problem behavior.
    explanation: >-
      This full-mutation fragile X caregiver study supports hyperactivity as a
      clinically measured behavioral dimension in fragile X syndrome.
- name: Attention Deficit Hyperactivity Disorder
  category: Behavioral
  frequency: FREQUENT
  description: >-
    Attention deficit hyperactivity disorder is a frequent behavioral phenotype
    in Orphanet's Fragile X syndrome profile and is clinically distinct from
    isolated hyperactivity.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007018 | Attention deficit hyperactivity disorder | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies attention deficit hyperactivity disorder as frequent in Fragile X syndrome.
- name: Anxiety
  category: Behavioral
  frequency: OCCASIONAL
  description: >-
    Anxiety is an occasional behavioral feature of fragile X syndrome and may
    occur with hyperactivity, shyness, and social avoidance.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:14730483
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most characteristic types of conduct seen in FXS include: language
      problems, lack of attention, hyperactivity, anxiety, shyness, behavioural
      problems, stereotypical hand flapping, gaze aversion, obstinacy and
      aggressiveness.
    explanation: >-
      This clinical comparison identifies anxiety as a characteristic fragile
      X behavioral feature linked to the genetic disorder.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000739 | Anxiety | Occasional (29-5%)"
    explanation: Orphanet's curated HPO table classifies anxiety as occasional in Fragile X syndrome.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Seizures occur in a minority of individuals with fragile X syndrome,
    commonly with childhood focal seizure or EEG patterns and generally
    favorable remission in reported cohorts.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:12418611
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures occurred in 15 males (13.3%) and one female (4.8%): of these, 12 had partial seizures.
    explanation: >-
      This cohort supports seizures as a recurrent neurological manifestation
      of fragile X syndrome.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet's curated HPO table classifies seizures as occasional in Fragile X syndrome.
- name: Delayed Speech and Language Development
  category: Neurological
  frequency: FREQUENT
  description: >-
    Delayed speech and language development is part of the neurodevelopmental
    phenotype spectrum recorded for Fragile X syndrome.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000750 | Delayed speech and language development | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies delayed speech and language development as frequent in Fragile X syndrome.
- name: Abnormality of Speech or Vocalization
  category: Neurological
  frequency: VERY_FREQUENT
  description: >-
    Abnormality of speech or vocalization is a very frequent feature of Fragile
    X syndrome, encompassing broad expressive speech and vocalization
    abnormalities.
  phenotype_term:
    preferred_term: Abnormality of speech or vocalization
    term:
      id: HP:0002167
      label: Abnormal speech pattern
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002167 | Abnormality of speech or vocalization | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies abnormality of speech or vocalization as very frequent in Fragile X syndrome.
- name: Hypotonia
  category: Neurological
  frequency: FREQUENT
  description: >-
    Hypotonia is a frequent motor feature in Orphanet's Fragile X syndrome HPO
    profile.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001252 | Hypotonia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies hypotonia as frequent in Fragile X syndrome.
- name: Macroorchidism
  category: Genitourinary
  frequency: VERY_FREQUENT
  description: >-
    Macroorchidism is a characteristic male physical feature, becoming most
    apparent after later childhood and puberty.
  phenotype_term:
    preferred_term: Macroorchidism
    term:
      id: HP:0000053
      label: Macroorchidism
  evidence:
  - reference: PMID:9678703
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This clinical review identifies macroorchidism as part of the fragile X
      physical phenotype.
  - reference: PMID:8190590
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Macroorchidism is one of the most well-described clinical characteristics of men with fragile X syndrome, but little information has been available regarding macroorchidism in prepubertal boys with fragile X.
    explanation: >-
      This study supports macroorchidism as a well-described male clinical
      characteristic and clarifies age-related expression.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000053 | Macroorchidism | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies macroorchidism as very frequent in Fragile X syndrome.
- name: Elongated Face
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    A long face is part of the characteristic fragile X physical gestalt and can
    become more apparent with age.
  phenotype_term:
    preferred_term: Long face
    term:
      id: HP:0000276
      label: Long face
  evidence:
  - reference: PMID:9678703
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This directly supports long face as part of the fragile X physical
      phenotype.
  - reference: PMID:8237919
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This supports long face across affected males and females.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000276 | Long face | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies long face as frequent in Fragile X syndrome.
- name: Large Ears
  category: Craniofacial
  frequency: FREQUENT
  description: >-
    Large or prominent ears are a common craniofacial feature of fragile X
    syndrome.
  phenotype_term:
    preferred_term: Large ears
    term:
      id: HP:0000400
      label: Macrotia
  evidence:
  - reference: PMID:9678703
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The fragile X syndrome is characterised by mental retardation, behavioural features, and physical features, such as a long face with large protruding ears and macro-orchidism.
    explanation: >-
      This directly supports large/protruding ears as part of the fragile X
      physical phenotype.
  - reference: PMID:8237919
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This supports prominent ears across affected males and females.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000400 | Macrotia | Frequent (79-30%)"
    explanation: Orphanet's curated HPO table classifies macrotia, the HPO term used here, as frequent in Fragile X syndrome.
- name: Chronic Otitis Media
  category: Otolaryngological
  frequency: VERY_FREQUENT
  description: >-
    Chronic otitis media is a very frequent otological comorbidity in Fragile X
    syndrome.
  phenotype_term:
    preferred_term: Chronic otitis media
    term:
      id: HP:0000389
      label: Chronic otitis media
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000389 | Chronic otitis media | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies chronic otitis media as very frequent in Fragile X syndrome.
- name: Joint Hypermobility
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: >-
    Hyperextensible joints are part of the connective-tissue physical phenotype
    in fragile X syndrome.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:8237919
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The physical features of fragile X, including a long face, prominent ears, and hyperextensible joints, are present in affected males and females.
    explanation: >-
      This directly supports hyperextensible joints as part of the fragile X
      physical phenotype.
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001382 | Joint hypermobility | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies joint hypermobility as very frequent in Fragile X syndrome.
- name: Pes Planus
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  description: >-
    Pes planus is a frequent connective-tissue and musculoskeletal feature in
    Orphanet's Fragile X syndrome phenotype profile.
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: ORPHA:908
    reference_title: "Fragile X syndrome (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001763 | Pes planus | Very frequent (99-80%)"
    explanation: Orphanet's curated HPO table classifies pes planus as very frequent in Fragile X syndrome.
biochemical:
- name: FMRP
  presence: Absent or reduced
  context: Absent in full-mutation males; variably reduced in females and mosaic individuals.
  evidence:
  - reference: PMID:27713816
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Such expanded alleles, known as full mutation (FM) alleles, are epigenetically silenced in differentiated cells thus resulting in the loss of FMRP, a protein important for learning and memory.
    explanation: >-
      This supports FMRP loss as the biochemical consequence of full-mutation
      FMR1 silencing.
genetic:
- name: FMR1
  gene_term:
    preferred_term: FMR1
    term:
      id: hgnc:3775
      label: FMR1
  association: Causative full-mutation CGG repeat expansion
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    X-linked repeat expansion disorder. Full-mutation alleles have more than
    200 CGG repeats in the FMR1 5' UTR and usually silence FMR1 expression.
  variants:
  - name: FMR1 full-mutation CGG repeat expansion
    description: >-
      Pathogenic expansion of the FMR1 5' UTR CGG repeat above 200 repeats,
      associated with methylation-mediated loss of FMR1 expression and FMRP.
    gene:
      preferred_term: FMR1
      term:
        id: hgnc:3775
        label: FMR1
    type: trinucleotide repeat expansion
    clinical_significance: PATHOGENIC
    functional_effects:
    - function: FMR1 expression
      regulatory_category: LOE
      regulatory_element_type: PROMOTER
      description: >-
        Repeat expansion and methylation abolish or markedly reduce FMR1
        expression across affected tissues.
  evidence:
  - reference: PMID:28420439
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a CGG expansion (>200 triplets) in the 5' UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS.
    explanation: >-
      This review supports FMR1 as the causal gene and identifies full-mutation
      CGG repeat expansion as the dominant pathogenic variant class.
  - reference: PMID:24346713
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Fragile X syndrome (FXS) is caused by mutations in the fragile X mental retardation 1 (FMR1) gene.
    explanation: >-
      This supports the causal FMR1 gene-disease relationship.
  - reference: CGGV:assertion_e491d278-7123-434c-8de3-46e16afb4037-2019-06-03T160000.000Z
    reference_title: "FMR1 / fragile X syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "FMR1 | HGNC:3775 | fragile X syndrome | MONDO:0010383 | XL | Definitive"
    explanation: ClinGen classifies the FMR1-fragile X syndrome gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Behavioral Therapy
  treatment_term:
    preferred_term: applied behavior analysis therapy
    term:
      id: MAXO:0001359
      label: applied behavior analysis therapy
  description: Applied behavior analysis and educational interventions for cognitive and behavioral symptoms.
- name: Speech Therapy
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  description: Language and communication support.
- name: Stimulant Medications
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: CNS Stimulant
      term:
        id: NCIT:C47795
        label: CNS Stimulant
  description: For attention deficit and hyperactivity symptoms.
- name: SSRIs
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Selective Serotonin Reuptake Inhibitor
      term:
        id: NCIT:C94725
        label: Selective Serotonin Reuptake Inhibitor
  description: For anxiety and mood symptoms.
- name: Genetic Counseling
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  description: Family screening for FMR1 expansion carriers, prenatal testing options.
clinical_trials:
- name: NCT02920892
  phase: PHASE_III
  status: COMPLETED
  description: >-
    FXLEARN phase 3 randomized trial of AFQ056/mavoglurant for language
    learning in young children with fragile X syndrome; the published trial did
    not show significant benefit over placebo on the primary WCS language
    outcome.
  target_phenotypes:
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: clinicaltrials:NCT02920892
    reference_title: Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The purpose of this clinical trial is to investigate the impact of AFQ056
      on language learning in 3-6 year old children with Fragile X Syndrome
      (FXS).
    explanation: >-
      ClinicalTrials.gov documents the AFQ056 language-learning trial in young
      children with fragile X syndrome.
  - reference: PMID:37651202
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although both groups made language progress and there were no safety
      issues, the change in WCS score during the placebo-controlled period was
      not significantly different between the AFQ056 and placebo-treated
      groups, nor were there any significant between-group differences in
      change in any secondary measures.
    explanation: >-
      The published FXLEARN report supports the completed phase 3 trial and its
      negative primary and secondary efficacy results.
- name: NCT03569631
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2a randomized double-blind crossover trial of BPN14770/zatolmilast in
    adult males with fragile X syndrome, with published cognition, language,
    daily-functioning, and EEG biomarker analyses.
  target_phenotypes:
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: clinicaltrials:NCT03569631
    reference_title: A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a single-center, randomized, double-blind, 2-period crossover
      study to explore the effects of BPN14770 on cognitive function and
      behavior in subjects with Fragile X Syndrome.
    explanation: >-
      ClinicalTrials.gov documents the BPN14770 crossover trial in adult males
      with fragile X syndrome.
  - reference: DOI:10.1186/s13229-024-00626-0
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A recent phase 2a clinical trial testing BPN14770, a phosphodiesterase 4D
      inhibitor, showed improved cognition in 30 adult males with FXS on drug
      relative to placebo.
    explanation: >-
      The Molecular Autism biomarker analysis supports the phase 2a BPN14770
      trial and its reported cognition signal.

references:
- reference: PMID:20301558
  title: "FMR1 Disorders."
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:20301558

FMR1 Disorders.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 50 citations 2026-04-25T22:42:57.048086

1. Disease Information

1.1 Overview

FXS is characterized by a broad phenotype including developmental delay, intellectual disability, behavioral dysregulation (anxiety, hyperactivity/ADHD traits, aggression), autistic features, and a set of physical findings (e.g., macroorchidism in males after puberty). (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

1.2 Key identifiers and synonyms (available from retrieved sources)

OMIM: 300624 (ciaccio2017fragilexsyndrome pages 1-2)
Gene: FMR1; locus Xq27.3 (ciaccio2017fragilexsyndrome pages 1-2)
Common synonym: Martin–Bell syndrome (ciaccio2017fragilexsyndrome pages 1-2)

ICD-10/ICD-11, MeSH, Orphanet/ORPHAcode: Not extractable from the retrieved documents; these need direct retrieval from ICD and Orphanet/MeSH resources.

1.3 Data provenance

The information summarized here is derived from aggregated disease-level resources (peer-reviewed reviews and clinical trial publications), plus primary studies (e.g., population newborn screening study; interventional trials). (berrykravis2024effectsofafq056 pages 1-2, seng2024longitudinalfollowupof pages 1-2, coffee2009incidenceoffragile media 983b62aa)

1.4 Compact identifiers/threshold summary

Item	Value	Source / publication date	URL	Citation
Disease name	Fragile X syndrome (FXS)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 1-3)
OMIM identifier	OMIM: 300624	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
Causal gene	FMR1	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
Cytogenetic locus	Xq27.3	Ciaccio et al., 2017; Volianskis, 2024	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2, volianskis2024alterationsinsynaptic pages 15-19)
Common alternate names / synonyms	Martin-Bell syndrome; historical “fragile X mental retardation” terminology appears in older literature	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
Molecular mechanism summary	CGG trinucleotide-repeat expansion in the 5′ UTR of FMR1 causes hypermethylation/silencing of FMR1 and loss of FMRP in full-mutation FXS	Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: normal	5–44 repeats (Ciaccio 2017); ~5–55 repeats (van der Lei & Kooy 2025); about 5–40 repeats (Genovese 2025)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: gray zone / intermediate	45–54 repeats	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)
CGG repeat range: premutation	~55–200 repeats (Ciaccio 2017); 55–200 repeats (Genovese 2025; van der Lei & Kooy 2025)	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
CGG repeat range: full mutation	>200 repeats	Ciaccio et al., 2017; Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.1186/s13052-017-0355-y ; https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(ciaccio2017fragilexsyndrome pages 1-2, genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 4-6)
Prevalence estimate	~1 in 4,000 males and ~1 in 8,000 females	Genovese & Butler, 2025; van der Lei & Kooy, 2025	https://doi.org/10.3390/genes16020149 ; https://doi.org/10.3390/biomedicines13040805	(genovese2025systematicreviewfragile pages 2-4, de2025fromdiscoveryto pages 1-3)
Alternate prevalence estimates reported in literature	~1:5,000–7,000 males and ~1:4,000–6,000 females	Ciaccio et al., 2017	https://doi.org/10.1186/s13052-017-0355-y	(ciaccio2017fragilexsyndrome pages 1-2)

Table: This table summarizes the core identifiers, synonyms, prevalence figures, and CGG repeat thresholds for Fragile X syndrome from key review sources. It is useful as a compact normalization reference for disease knowledge-base curation.

2. Etiology

2.1 Disease causal factors

Primary cause: A CGG repeat expansion in the 5′UTR of FMR1. Commonly used thresholds across sources: - Normal: ~5–55 repeats (or 5–44 in some classification) (de2025fromdiscoveryto pages 4-6, ciaccio2017fragilexsyndrome pages 1-2) - Premutation: 55–200 repeats (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4) - Full mutation (FXS): >200 repeats, associated with hypermethylation/silencing and loss of FMRP (de2025fromdiscoveryto pages 4-6, genovese2025systematicreviewfragile pages 2-4)

Mechanistically, when repeat length exceeds ~200, methylation and chromatin changes (histone deacetylation, heterochromatin formation) contribute to transcriptional silencing and loss of FMRP. (volianskis2024alterationsinsynaptic pages 15-19)

Less common molecular causes: Non-repeat FMR1 alterations such as deletions/duplications and SNVs account for <1% of molecular diagnoses in one review. (ciaccio2017fragilexsyndrome pages 1-2)

2.2 Risk factors

Sex: males are generally more severely affected due to having a single X chromosome. (genovese2025systematicreviewfragile pages 2-4)
Repeat instability/anticipation: expansion from premutation to full mutation occurs predominantly during maternal transmission (anticipation). (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

2.3 Protective factors

No specific genetic or environmental “protective factors” were identified within the retrieved evidence corpus. However, mosaicism (cells with smaller/unmethylated alleles) is associated with better cognitive outcomes, implying partial protection at the molecular/cellular level. (genovese2025systematicreviewfragile pages 7-9)

2.4 Gene–environment interactions

The retrieved corpus did not provide specific, well-supported gene–environment interaction claims for classic FXS.

3. Phenotypes

3.1 Core neurodevelopmental phenotype

Intellectual disability / cognitive impairment: core feature; one review reports typical IQ <70 with male average ~40–55 and female ~65–70. (de2025fromdiscoveryto pages 3-4)
ASD/autistic features: common; ~30–50% of males and ~20% females have autistic behaviors by direct assessment in one review (de2025fromdiscoveryto pages 3-4); a systematic review reports comorbid ASD in “just over 40%” overall (46% males, 16% females). (genovese2025systematicreviewfragile pages 7-9)
Behavioral features: hyperactivity, anxiety, aggression, attention deficits, sensory hyperarousal; ADHD criteria frequently met. (de2025fromdiscoveryto pages 3-4)

3.2 Neurologic comorbidity

Seizures: estimates include ~15–20% of males and ~5% of females (de2025fromdiscoveryto pages 4-6) and 10–20% of boys and 5–10% of girls (ciaccio2017fragilexsyndrome pages 2-3).
EEG abnormalities: ~74–75% of young children show EEG abnormalities; ~1/3 remit by mid-childhood in one systematic review. (genovese2025systematicreviewfragile pages 7-9)

3.3 Physical phenotype and medical comorbidities (examples with frequency where available)

Macroorchidism: 63–95% (males) (ciaccio2017fragilexsyndrome pages 2-3)
Obesity: 53–61% (ciaccio2017fragilexsyndrome pages 2-3)
Recurrent otitis media: 47–97% (ciaccio2017fragilexsyndrome pages 2-3)
GI complaints: ~31% (ciaccio2017fragilexsyndrome pages 2-3)
Strabismus: 30–55% (young males) (genovese2025systematicreviewfragile pages 6-7)

3.4 Developmental timing and progression

Developmental delay is typically recognized in infancy/early childhood (boys as early as ~6 months; girls ~1 year in a systematic review). (genovese2025systematicreviewfragile pages 7-9)

3.5 Quality-of-life impact

FXS-associated ASD features “emerge in early childhood and impair daily functioning,” and FXS can impair adaptive skills needed for communication, self-care, and social participation, consistent with substantial QOL impact. (de2025fromdiscoveryto pages 3-4)

3.6 Suggested HPO terms (best-effort, not extracted from evidence text)

These are standard phenotype mappings consistent with the reported clinical picture: - Intellectual disability (HP:0001249) - Global developmental delay (HP:0001263) - Autism (HP:0000717) - Seizures (HP:0001250) - Anxiety (HP:0000739) - Attention deficit hyperactivity disorder (HP:0007018) - Macroorchidism (HP:0000049) - Large ears (HP:0000400) - Strabismus (HP:0000486) - Sleep disturbance (HP:0002360)

4. Genetic / Molecular Information

4.1 Causal gene

FMR1 (Xq27.3). (ciaccio2017fragilexsyndrome pages 1-2)

4.2 Pathogenic variant class

Repeat expansion in the 5′UTR CGG tract is the dominant mechanism (>99% of cases in one review), with full mutation generally >200 repeats leading to methylation and silencing. (ciaccio2017fragilexsyndrome pages 1-2, de2025fromdiscoveryto pages 4-6)

4.3 Functional consequence

Loss of function of FMR1 at the expression level (epigenetic silencing) leads to loss of FMRP. (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

4.4 Modifier mechanisms

Mosaicism (size or methylation mosaicism) contributes to variable FMRP expression and phenotype variability; mosaicism with partially unmethylated alleles is associated with better cognitive functioning. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

4.5 Epigenetic information

FXS full mutation is associated with hypermethylation of FMR1, transcriptional silencing, and heterochromatinization. (volianskis2024alterationsinsynaptic pages 15-19)

5. Environmental Information

FXS is primarily genetic. The retrieved evidence corpus did not provide specific validated environmental exposures that cause classic FXS (as opposed to modifying symptoms). Supportive-care and early intervention (environmental/behavioral supports) affect outcomes but are not etiologic.

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

FMR1 CGG full mutation (>200 repeats) in 5′UTR → 2. hypermethylation and chromatin silencing of FMR1 → 3. loss of FMRP (RNA-binding translational regulator) → 4. dysregulated transport/local translation of synaptic mRNAs and altered protein synthesis → 5. abnormal dendritic spine maturation (immature/elongated spines), altered synaptic plasticity and circuit function → 6. excitatory/inhibitory imbalance and hyperexcitability involving glutamatergic (mGluR5) and GABAergic systems → 7. neurodevelopmental phenotype (ID, ASD traits, behavioral dysregulation, seizures). (de2025fromdiscoveryto pages 4-6, volianskis2024alterationsinsynaptic pages 15-19)

6.2 Implicated pathways (examples)

mGluR5 signaling dysregulation (loss of FMRP’s normal negative regulation) is emphasized as a major mechanistic framework. (de2025fromdiscoveryto pages 4-6)
GABAergic deficits and E/I imbalance are repeatedly described. (de2025fromdiscoveryto pages 4-6)
cAMP signaling abnormalities are noted in human cell lines and models, motivating PDE inhibition strategies. (genovese2025systematicreviewfragile pages 12-13)

6.3 Suggested GO biological process terms (best-effort)

Synaptic signaling (GO:0099536)
Regulation of translation (GO:0006417)
Synaptic plasticity (GO:0048167)
Dendritic spine development (GO:0060998)
Regulation of excitatory postsynaptic potential (GO:0099528)

6.4 Suggested CL cell types (best-effort)

Cortical pyramidal neuron (CL:0000540)
GABAergic interneuron (CL:0000099)

6.5 Suggested UBERON anatomical structures (best-effort)

Cerebral cortex (UBERON:0000956)
Hippocampus (UBERON:0001954)
Prefrontal cortex (UBERON:0001870)

6.6 Molecular profiling / biomarkers (selected)

EEG-based translational biomarkers are emphasized as objective measures; BPN14770 studies specifically analyze auditory N1 ERP and peak alpha frequency (PAF) as treatment-linked physiology measures. (norris2024auditoryn1eventrelated pages 1-2, norris2025rocanalysisof pages 8-10)

7. Anatomical Structures Affected

Organ/system level

Primary involvement is the central nervous system with downstream behavioral, cognitive, and neuropsychiatric manifestations. (de2025fromdiscoveryto pages 4-6, de2025fromdiscoveryto pages 3-4)

Tissue/cell level

FXS pathophysiology is discussed in terms of synaptic dysfunction in neuronal circuits and altered excitatory/inhibitory balance (glutamatergic and GABAergic synapses). (de2025fromdiscoveryto pages 4-6, ntoulas2024multilevelprofilingof pages 1-2)

8. Temporal Development

Onset

Typically early (infancy/early childhood) with developmental delays. (genovese2025systematicreviewfragile pages 7-9)

Progression

FXS is generally described as not markedly worsening over time; however, males may show IQ decline during development/early puberty in some analyses. (genovese2025systematicreviewfragile pages 7-9, genovese2025systematicreviewfragile pages 2-4)

9. Inheritance and Population

9.1 Inheritance

X-linked dominant inheritance pattern is described, with dynamic repeat expansion/anticipation, especially during maternal transmission. (genovese2025systematicreviewfragile pages 2-4, volianskis2024alterationsinsynaptic pages 15-19)

9.2 Epidemiology (selected statistics)

Prevalence: ~1 in 4,000 males and 1 in 8,000 females (genovese2025systematicreviewfragile pages 2-4).
Premutation carrier frequency: ~1 in 250 females and 1 in 800 males (premutation defined 55–200 repeats). (genovese2025systematicreviewfragile pages 2-4)

Newborn-screening derived incidence: In a population screen of 36,124 newborn males, 7 full-mutation FXS cases were confirmed, corresponding to an incidence of 1 in 5161 (95% CI 1/10,653–1/2500). (coffee2009incidenceoffragile media 983b62aa)

10. Diagnostics

10.1 Molecular diagnostic approach (current standard in retrieved sources)

Postnatal testing often includes PCR combined with Southern blot and/or triplet-primed PCR (TP-PCR) to detect FMR1 repeat expansions and assess size. (genovese2025systematicreviewfragile pages 2-4)
Because pathogenicity depends strongly on methylation/silencing, testing commonly includes methylation-sensitive methods. (genovese2025systematicreviewfragile pages 2-4)

10.2 Newborn screening / early detection

A newborn screening approach based on quantitative FMR1 methylation in dried blood spots was developed and used to directly measure incidence in a large male newborn cohort, supporting feasibility of early detection. (coffee2009incidenceoffragile media 983b62aa)

10.3 Prenatal diagnosis

Prenatal diagnostic options described include chorionic villus sampling and amniocentesis when there is family history or known carrier status. (genovese2025systematicreviewfragile pages 2-4)

10.4 Differential diagnosis

Not systematically extractable from the retrieved excerpts.

11. Outcome / Prognosis

FXS is generally not considered directly life-threatening and does not typically show marked neurodegenerative worsening as a primary feature, but it produces lifelong functional challenges requiring support. (genovese2025systematicreviewfragile pages 2-4)

Premutation carriers have distinct late-onset risks (e.g., FXTAS, FXPOI), but these are separate fragile X–associated disorders rather than classic full-mutation FXS. (genovese2025systematicreviewfragile pages 7-9, volianskis2024alterationsinsynaptic pages 15-19)

12. Treatment

12.1 Current clinical practice (real-world implementation)

No FDA-approved disease-modifying medications exist for FXS; management is largely symptom-based and multidisciplinary, including behavioral therapies, speech-language therapy, applied behavior analysis, parent training, and CBT to address communication and behavioral/psychiatric symptoms. (genovese2025systematicreviewfragile pages 10-12)

12.2 Recent clinical trial developments (2023–2024 prioritized)

Key recent peer-reviewed trials and translational biomarker papers: - AFQ056 (mavoglurant) FXLEARN trial (2024, JCI): 99 randomized young children; no benefit over placebo on primary WCS language outcome; strong example of translational gap for mGluR5 NAMs. (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5) - Metformin longitudinal follow-up (2024, Frontiers in Psychology): open-label follow-up in n=26 (6–25 years) over 1–3 years; nonverbal IQ and adaptive function stable with no significant decline. (seng2024longitudinalfollowupof pages 3-4) - BPN14770 (zatolmilast) biomarker analysis (2024, Molecular Autism): N1 ERP amplitude correlated with serum drug concentration (rho=0.608, p=0.036 in period-1 drug recipients), supporting an exposure–physiology link; clinical improvements in cognition/language/daily functioning were reported in the trial background. (norris2024auditoryn1eventrelated pages 2-4, norris2024auditoryn1eventrelated pages 1-2)

12.3 Targeted/symptomatic agents with mixed evidence

Reviews summarize mixed/negative outcomes for multiple targeted approaches, with occasional subgroup signals: - Arbaclofen (GABA-B agonist): Phase 3 trials negative overall; some pediatric irritability benefits at higher doses. (protic2025targeteddrugdevelopment pages 4-5) - Ganaxolone (GABAA PAM): safe but primary endpoint negative overall; possible subgroup benefits. (protic2025targeteddrugdevelopment pages 4-5) - Gaboxadol (OV101): early signal with ~60% CGI-I responders in a small study summarized in reviews. (protic2025targeteddrugdevelopment pages 4-5) - Cannabidiol / ZYN002: phase 3 negative overall with post hoc methylation-defined subgroup benefit reported in a review summary. (protic2025razvojciljanefarmakoterapije pages 5-6)

A compact cross-intervention summary is provided below: | Intervention | Mechanism / target | Key study / design | Sample size / population | Primary endpoint(s) / main measures | Main findings reported | NCT ID(s) | Publication date | URL | Citation | |---|---|---|---|---|---|---|---|---|---| | AFQ056 (mavoglurant) | mGluR5 negative allosteric modulator | FXLEARN: large multisite randomized, double-blind, placebo-controlled trial with 4-month placebo lead-in, 2-month dose optimization, 6-month treatment; all participants also received parent-implemented language intervention | 110 enrolled; 99 randomized (50 AFQ056, 49 placebo); 91 completed placebo-controlled period; children age ~3–6 years with FXS | Primary: Weighted Communication Scale (WCS); secondary: objective and parent-reported cognitive/language measures including MSEL, PLS-5, Vineland-3 | No significant difference vs placebo on WCS or secondary measures; both groups improved in language over time; lower-baseline communication subgroup did worse on AFQ056 than placebo in subgroup analysis; no major safety signal | NCT02920892 | 2024-08 | https://doi.org/10.1172/jci171723 | (berrykravis2024effectsofafq056 pages 1-2, berrykravis2024effectsofafq056 pages 3-5, berrykravis2024effectsofafq056 pages 6-7, berrykravis2024effectsofafq056 pages 9-10) | | Metformin | AMPK activation; proposed reduction of MMP-9 / modulation of dysregulated signaling | Open-label longitudinal follow-up after prior controlled exposure; repeated cognitive and adaptive behavior testing over 1–3 years | 26 individuals with FXS (22 males, 4 females), ages 6–25 years | Leiter-III nonverbal IQ; Vineland-3 adaptive behavior | Overall nonverbal IQ and adaptive behavior remained stable; no significant decline over follow-up; small sample and no control group limit inference | NCT05120505 ongoing pediatric RCT also identified in registry; separate follow-up paper is open-label longitudinal | 2024-06 | https://doi.org/10.3389/fpsyg.2024.1305597 | (seng2024longitudinalfollowupof pages 1-2, seng2024longitudinalfollowupof pages 3-4, seng2024longitudinalfollowupof pages 2-3, NCT05120505 chunk 1) | | BPN14770 (zatolmilast) | PDE4D inhibitor; increases cAMP signaling | Phase 2a placebo-controlled crossover trial with EEG biomarker analyses; later exploratory ROC/EEG work | 30 adult males with FXS; EEG subsets smaller due to artifact/data loss | Clinical cognition/language/daily function measures; auditory N1 ERP amplitude; exploratory peak alpha frequency (PAF) | Clinical improvements in cognition, language, and daily functioning were reported; N1 amplitude showed correlation with serum drug concentration, stronger in period-1 drug recipients (rho = 0.608, p = 0.036, N = 12); exploratory PAF increased vs baseline and may be a scalable biomarker | NCT03569631 | 2024-11 (biomarker paper); 2025-05 (exploratory preprint) | https://doi.org/10.1186/s13229-024-00626-0 ; https://doi.org/10.1101/2025.05.29.25328581 | (norris2024auditoryn1eventrelated pages 1-2, norris2024auditoryn1eventrelated pages 2-4, norris2025rocanalysisof pages 1-4, norris2025rocanalysisof pages 8-10) | | Arbaclofen (STX209) | GABA-B agonist | Two Phase 3 placebo-controlled trials in children and in adolescents/adults | Pediatric and adult/adolescent cohorts; registry lists 172 children in NCT01325220 and 125 adolescents/adults in NCT01282268 | Primary behavioral/social withdrawal outcomes; irritability subscales and parent-rated outcomes reported in reviews | Overall primary endpoints not met; pediatric highest-dose group showed improvements on ABC-CFX Irritability and Parenting Stress Index / parent-rated forms; generally well tolerated | NCT01325220; NCT01282268 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01325220 ; https://clinicaltrials.gov/study/NCT01282268 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) | | Ganaxolone | GABAA positive allosteric modulator / neurosteroid | Phase 2 randomized crossover trial in children/adolescents | n = 59 in registry/review | Primary: CGI-I | Safe but did not differ from placebo on primary CGI-I endpoint overall; post hoc subgroup benefits reported in participants with higher anxiety or lower cognition | NCT01725152 | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01725152 | (protic2025targeteddrugdevelopment pages 4-5) | | Gaboxadol (OV101) | GABAA agonist / extrasynaptic GABAergic modulation | Phase 2a ROCKET study; additional recruiting single-dose adult study noted in review | ~23 participants in phase 2a response analysis | CGI-I and clinician/caregiver-rated behavioral measures | Well tolerated; about 60% classified as CGI-I responders in phase 2a; initial efficacy signal on hyperactivity, irritability, stereotypy, and anxiety in reported review summaries | NCT06334419 recruiting study noted; ROCKET NCT not provided in evidence excerpt | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 8-9) | | Cannabidiol / ZYN002 | Endocannabinoid system modulation; transdermal CBD formulation | Phase 1/2 open-label and Phase 3 CONNECT-FX reviewed; post hoc methylation-stratified analyses | Sample size not stated in provided evidence excerpt | ADAMS and phase 3 primary endpoint not specified in excerpt | Open-label study showed safety and ADAMS reduction; CONNECT-FX failed primary endpoint overall, but subgroup with ≥90% FMR1 promoter methylation showed benefit, motivating RECONNECT | NCT04977986 recruiting study noted in review | 2025 review summary | https://doi.org/10.5937/medi0-60213 ; https://doi.org/10.3390/biomedicines13040805 | (protic2025razvojciljanefarmakoterapije pages 5-6, de2025fromdiscoveryto pages 8-9) | | Older mGluR5 program overview (mavoglurant / basimglurant) | mGluR5 negative allosteric modulation | Earlier adult/adolescent Phase 2/2b and extension trials summarized in reviews | Small crossover adult mavoglurant study in 30 adult males; larger adolescent/adult trials listed in reviews/registry | Behavioral endpoints; FXLEARN later used WCS for language learning in young children | Initial small subgroup signal in fully methylated cases did not replicate; larger Phase 2b trials and basimglurant Phase II studies were negative, contributing to skepticism about direct mGluR5 translation from animal models | NCT01357239; NCT01348087; NCT01433354; NCT02920892 | 2024-08 and 2025 review summaries | https://doi.org/10.1172/jci171723 ; https://doi.org/10.5937/medi0-60213 ; https://clinicaltrials.gov/study/NCT01357239 | (berrykravis2024effectsofafq056 pages 1-2, protic2025targeteddrugdevelopment pages 4-5, de2025fromdiscoveryto pages 9-10) |

Table: This table summarizes key Fragile X syndrome therapeutic studies and trial programs emphasized in the gathered evidence, including recent 2024 findings and older targeted treatment programs. It is useful for comparing mechanisms, study designs, endpoints, outcomes, and trial identifiers across leading pharmacologic approaches.

12.4 Suggested MAXO terms (best-effort)

Pharmacotherapy (MAXO:0000058)
Behavioral therapy (MAXO:0000506)
Speech therapy (MAXO:0001193)
Genetic counseling (MAXO:0000070)

13. Prevention

Primary prevention

Because FXS is inherited, prevention focuses on genetic counseling and reproductive planning for carriers. (genovese2025systematicreviewfragile pages 2-4)

Secondary prevention (screening/early detection)

Newborn screening by methylation assay in dried blood spots has been demonstrated and used to estimate incidence, supporting a potential early-intervention pathway. (coffee2009incidenceoffragile media 983b62aa)

Tertiary prevention

Multidisciplinary management and early developmental/behavioral interventions aim to reduce disability and improve long-term functioning. (genovese2025systematicreviewfragile pages 12-13, genovese2025systematicreviewfragile pages 10-12)

14. Other Species / Natural Disease

The retrieved evidence focuses on model organisms rather than naturally occurring veterinary disease. No naturally occurring non-human clinical syndrome analogous to human FXS was identified in the provided corpus.

15. Model Organisms

A diverse model ecosystem is used to study FMRP function and therapeutics: - Mouse (Fmr1 KO): dominant in vivo model; captures many phenotypes (immature spines, altered LTP/LTD, hyperactivity/anxiety/social changes); key limitations include species differences and differences in timing of FMRP expression vs humans (humans express FMR1 until at least week 10 gestation). (de2025fromdiscoveryto pages 6-8) - Rat (Fmr1 KO): proposed to offer added translational validity; a 2024 study combined behavior, hippocampal electrophysiology, and RNA-seq and found hyperactivity/cognitive deficits plus glutamatergic/GABAergic alterations in PFC and hippocampus. (ntoulas2024multilevelprofilingof pages 1-2) - Drosophila / zebrafish: useful for conserved genetics/pathway discovery; limitations include species differences. (sandoval2024fromwingsto pages 2-3) - Human iPSC neurons and 3D organoids/assembloids: enable study of patient-derived epigenetic FMR1 silencing and human-specific neurodevelopment; limitations include immaturity, reproducibility issues, and inability to model behavior. (sandoval2024fromwingsto pages 5-7)

Expert opinions / analysis (from authoritative sources in retrieved corpus)

A consistent expert view in recent reviews is that translation from strong preclinical signals to clinical efficacy has been limited by patient heterogeneity, inconsistent outcomes, and the need for objective biomarkers and better trial design—highlighted in the context of mGluR5 NAM programs and the field’s shift toward biomarkers (EEG), stratification (methylation status), and gene/reactivation strategies (ASOs, CRISPR-based approaches). (de2025fromdiscoveryto pages 18-19, de2025fromdiscoveryto pages 13-15, berrykravis2024effectsofafq056 pages 1-2)

Key recent statistics (selected)

Prevalence: ~1/4,000 males and ~1/8,000 females. (genovese2025systematicreviewfragile pages 2-4)
Premutation frequency: ~1/250 females; ~1/800 males. (genovese2025systematicreviewfragile pages 2-4)
Newborn-screening incidence in males: 1/5,161 (7/36,124). (coffee2009incidenceoffragile media 983b62aa)
Comorbid ASD in FXS: ~46% males and 16% females (“just over 40% overall”). (genovese2025systematicreviewfragile pages 7-9)
Seizure prevalence: ~15–20% males and ~5% females (review estimate). (de2025fromdiscoveryto pages 4-6)

Limitations of this report (evidence availability)

Specific ontology identifiers (MONDO ID, Orphanet ORPHAcode, MeSH, ICD-10/ICD-11) were not present in the retrieved documents and thus could not be extracted with full citation support.
Some requested sections (environmental risk/protective factors, formal diagnostic criteria, differential diagnosis, survival statistics) were not explicitly quantified in the retrieved excerpts.
Suggested ontology term mappings (HPO/GO/CL/UBERON/MAXO) are provided as best-effort standard mappings rather than extracted identifiers from the cited texts.

References

(de2025fromdiscoveryto pages 4-6): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(genovese2025systematicreviewfragile pages 2-4): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(de2025fromdiscoveryto pages 1-3): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(coffee2009incidenceoffragile media 983b62aa): Bradford Coffee, Krayton Keith, Igor Albizua, Tamika Malone, Julie Mowrey, Stephanie L. Sherman, and Stephen T. Warren. Incidence of fragile x syndrome by newborn screening for methylated fmr1 dna. American journal of human genetics, 85 4:503-14, Oct 2009. URL: https://doi.org/10.1016/j.ajhg.2009.09.007, doi:10.1016/j.ajhg.2009.09.007. This article has 558 citations and is from a highest quality peer-reviewed journal.
(de2025fromdiscoveryto pages 3-4): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(ciaccio2017fragilexsyndrome pages 1-2): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.
(berrykravis2024effectsofafq056 pages 1-2): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 1-2): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(volianskis2024alterationsinsynaptic pages 15-19): RE Volianskis. Alterations in synaptic plasticity in a mouse model of fragile x syndrome. Unknown journal, 2024.
(genovese2025systematicreviewfragile pages 7-9): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(ciaccio2017fragilexsyndrome pages 2-3): Claudia Ciaccio, Laura Fontana, Donatella Milani, Silvia Tabano, Monica Miozzo, and Susanna Esposito. Fragile x syndrome: a review of clinical and molecular diagnoses. Italian Journal of Pediatrics, Apr 2017. URL: https://doi.org/10.1186/s13052-017-0355-y, doi:10.1186/s13052-017-0355-y. This article has 223 citations and is from a peer-reviewed journal.
(genovese2025systematicreviewfragile pages 6-7): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(genovese2025systematicreviewfragile pages 12-13): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(norris2024auditoryn1eventrelated pages 1-2): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.
(norris2025rocanalysisof pages 8-10): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.
(ntoulas2024multilevelprofilingof pages 1-2): George Ntoulas, Charalampos Brakatselos, Gerasimos Nakas, Michail-Zois Asprogerakas, Foteini Delis, Leonidas J. Leontiadis, George Trompoukis, Costas Papatheodoropoulos, Dimitrios Gkikas, Dimitrios Valakos, Giannis Vatsellas, Panagiotis K. Politis, Alexia Polissidis, and Katerina Antoniou. Multi-level profiling of the fmr1 ko rat unveils altered behavioral traits along with aberrant glutamatergic function. Translational Psychiatry, Feb 2024. URL: https://doi.org/10.1038/s41398-024-02815-0, doi:10.1038/s41398-024-02815-0. This article has 10 citations and is from a peer-reviewed journal.
(genovese2025systematicreviewfragile pages 10-12): Ann C. Genovese and Merlin G. Butler. Systematic review: fragile x syndrome across the lifespan with a focus on genetics, neurodevelopmental, behavioral and psychiatric associations. Genes, 16:149, Jan 2025. URL: https://doi.org/10.3390/genes16020149, doi:10.3390/genes16020149. This article has 17 citations.
(berrykravis2024effectsofafq056 pages 3-5): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 3-4): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(norris2024auditoryn1eventrelated pages 2-4): Jordan E. Norris, Elizabeth M. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney, and Lauren E. Ethridge. Auditory n1 event-related potential amplitude is predictive of serum concentration of bpn14770 in fragile x syndrome. Molecular Autism, Nov 2024. URL: https://doi.org/10.1186/s13229-024-00626-0, doi:10.1186/s13229-024-00626-0. This article has 5 citations and is from a peer-reviewed journal.
(protic2025targeteddrugdevelopment pages 4-5): Dragana Protić, Maja Stojković, and Dejan Budimirović. Targeted drug development in fragile x syndrome: molecular medicine as a key tool in clinical pharmacology. Medicinska istrazivanja, pages 19-19, Jan 2025. URL: https://doi.org/10.5937/medi0-60213, doi:10.5937/medi0-60213. This article has 0 citations.
(protic2025razvojciljanefarmakoterapije pages 5-6): D Protic, M Stojkovic, and D Budimirovic. Razvoj ciljane farmakoterapije za fragilni x sindrom: molekularna medicina kao ključno sredstvo u kliničkoj …. Unknown journal, 2025.
(berrykravis2024effectsofafq056 pages 6-7): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(berrykravis2024effectsofafq056 pages 9-10): Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, Christopher S. Coffey, Merit Cudkowicz, Craig A. Erickson, Andrea McDuffie, David Hessl, Lauren Ethridge, Flora Tassone, Walter E. Kaufmann, Katherine Friedmann, Lauren Bullard, Anne Hoffmann, Jeremy Veenstra-VanderWeele, Kevin Staley, David Klements, Michael Moshinsky, Brittney Harkey, Jeff Long, Janel Fedler, Elizabeth Klingner, Dixie Ecklund, Michele Costigan, Trevis Huff, and Brenda Pearson. Effects of afq056 on language learning in fragile x syndrome. The Journal of Clinical Investigation, Aug 2024. URL: https://doi.org/10.1172/jci171723, doi:10.1172/jci171723. This article has 24 citations.
(seng2024longitudinalfollowupof pages 2-3): Panhaneath Seng, Federica Alice Maria Montanaro, Hazel Maridith Barlahan Biag, Maria Jimena Salcedo-Arellano, Kyoungmi Kim, Matthew Dominic Ponzini, Flora Tassone, Andrea Schneider, Leonard Abbeduto, Angela John Thurman, David Hessl, Francois V. Bolduc, Sebastien Jacquemont, Sarah Lippé, and Randi J. Hagerman. Longitudinal follow-up of metformin treatment in fragile x syndrome. Frontiers in Psychology, Jun 2024. URL: https://doi.org/10.3389/fpsyg.2024.1305597, doi:10.3389/fpsyg.2024.1305597. This article has 8 citations and is from a peer-reviewed journal.
(NCT05120505 chunk 1): Metformin in Children With Fragile X Syndrome. Children's Hospital of Fudan University. 2021. ClinicalTrials.gov Identifier: NCT05120505
(norris2025rocanalysisof pages 1-4): J. E. Norris, E. Berry-Kravis, Mark D. Harnett, Scott A. Reines, Melody A. Reese, Emma K. Auger Ph.D., Abigail H. Outterson Ph.D., Jeremiah Furman, Mark E. Gurney, and Ph.D Lauren E. Ethridge. Roc analysis of biomarker combinations in fragile x syndrome-specific clinical trials: evaluating treatment efficacy via exploratory biomarkers. MedRxiv, May 2025. URL: https://doi.org/10.1101/2025.05.29.25328581, doi:10.1101/2025.05.29.25328581. This article has 1 citations.
(de2025fromdiscoveryto pages 9-10): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 8-9): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 6-8): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(sandoval2024fromwingsto pages 2-3): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.
(sandoval2024fromwingsto pages 5-7): Soraya O. Sandoval, Natasha M. Méndez-Albelo, Zhiyan Xu, and Xinyu Zhao. From wings to whiskers to stem cells: why every model matters in fragile x syndrome research. Journal of Neurodevelopmental Disorders, Jun 2024. URL: https://doi.org/10.1186/s11689-024-09545-w, doi:10.1186/s11689-024-09545-w. This article has 3 citations and is from a peer-reviewed journal.
(de2025fromdiscoveryto pages 18-19): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.
(de2025fromdiscoveryto pages 13-15): Mathijs B. van der Lei and R. Frank Kooy. From discovery to innovative translational approaches in 80 years of fragile x syndrome research. Biomedicines, 13:805, Mar 2025. URL: https://doi.org/10.3390/biomedicines13040805, doi:10.3390/biomedicines13040805. This article has 6 citations.

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Subtypes

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Overview

1.2 Key identifiers and synonyms (available from retrieved sources)

1.3 Data provenance

1.4 Compact identifiers/threshold summary

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core neurodevelopmental phenotype

3.2 Neurologic comorbidity

3.3 Physical phenotype and medical comorbidities (examples with frequency where available)

3.4 Developmental timing and progression

3.5 Quality-of-life impact

3.6 Suggested HPO terms (best-effort, not extracted from evidence text)

4. Genetic / Molecular Information

4.1 Causal gene

4.2 Pathogenic variant class

4.3 Functional consequence

4.4 Modifier mechanisms

4.5 Epigenetic information

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

6.2 Implicated pathways (examples)

6.3 Suggested GO biological process terms (best-effort)

6.4 Suggested CL cell types (best-effort)

6.5 Suggested UBERON anatomical structures (best-effort)

6.6 Molecular profiling / biomarkers (selected)

7. Anatomical Structures Affected

Organ/system level

Tissue/cell level

8. Temporal Development

Onset

Progression

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology (selected statistics)

10. Diagnostics

10.1 Molecular diagnostic approach (current standard in retrieved sources)

10.2 Newborn screening / early detection

10.3 Prenatal diagnosis

10.4 Differential diagnosis

11. Outcome / Prognosis

12. Treatment

12.1 Current clinical practice (real-world implementation)

12.2 Recent clinical trial developments (2023–2024 prioritized)

12.3 Targeted/symptomatic agents with mixed evidence

12.4 Suggested MAXO terms (best-effort)

13. Prevention

Primary prevention

Secondary prevention (screening/early detection)

Tertiary prevention

14. Other Species / Natural Disease

15. Model Organisms

Expert opinions / analysis (from authoritative sources in retrieved corpus)

Key recent statistics (selected)

Limitations of this report (evidence availability)